DBV Technologies (NASDAQ:DBVT) Trading Down 7.4% – Here’s Why

Posted by George Bondi on Sep 11th, 2026

DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) dropped 7.4% during mid-day trading on Friday . The stock traded as low as $12.38 and last traded at $12.01. Approximately 122,596 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 289,946 shares. The stock had previously closed at $12.97.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Weiss Ratings lowered DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Citizens Jmp lifted their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a research report on Thursday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

Get Our Latest Stock Report on DBVT

DBV Technologies Price Performance

The company’s fifty day moving average is $14.37 and its 200-day moving average is $17.62. The stock has a market cap of $761.35 million, a PE ratio of -3.46 and a beta of -0.95.

Hedge Funds Weigh In On DBV Technologies

A number of institutional investors have recently modified their holdings of the stock. Artisan Partners Limited Partnership raised its position in DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after acquiring an additional 3,257,135 shares in the last quarter. Siren L.L.C. purchased a new stake in DBV Technologies in the 4th quarter worth approximately $35,606,000. Vivo Capital LLC boosted its position in DBV Technologies by 133.4% in the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after purchasing an additional 1,407,120 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,659,000. Finally, MPM Bioimpact LLC acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.